The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
New NCCN guidelines recognize the utility of MammaPrint for guiding anthracycline therapy selection in HR+/HER2- early-stage ...
The update is based on data from the FLEX study in patients with HR-positive, HER2-negative early-stage breast cancer.
The Viz Oncology Suite is a clinical decision support system that integrates seamlessly with the electronic health record to ...
World Cancer Day promotes awareness and patient-centered cancer care, marking the 25th anniversary of the Charter of Paris Against Cancer. The 'United by Unique' campaign highlights the individuality ...
PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...
NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...
The National Comprehensive Cancer Network celebrated its 30th anniversary with a series of presentations on cancer care practice changes—in both treatment and administration—plus new research, and ...
The National Comprehensive Cancer Network Oncology Research Program awards funding to researchers from Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic ...
The National Comprehensive Cancer Network Oncology Research Program announces funding for research projects to advance treatment for people with stage four breast cancer. Approximately 10% of people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback